Asciminib
About
Therapy type: Targeted therapy
Therapy strategy: BCR-ABL inhibition
Mappings
NCI Thesaurus: Asciminib (ncit:C114494)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) | BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| FDA (1) | ABL1 p.T315I, BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib | |
| FDA (2) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Asciminib | |
| EMA (1) | BCR::ABL1 | Chronic Myelogenous Leukemia | Asciminib |